-
Uncategorized4 weeks ago
Biopharma M&A maintains strength even as large deals wane
Biopharma’s deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one notable...
-
Uncategorized4 weeks agoSTAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctors
Takeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant and, consequently, violated federal law by...
-
Uncategorized4 weeks ago
ASGCT Q1 Landscape Report Paints Positive Picture for Gene and RNA Therapy
ASGCT Q1 Landscape Report Paints Positive Picture for Gene and RNA Therapy
-
Uncategorized4 weeks ago
Using Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain
Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherence
-
Uncategorized4 weeks agoFDA hold puts Aardvark Prader-Willi drug in limbo
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
-
Uncategorized4 weeks ago
Candel reports prostate cancer drug’s long-term data ahead of FDA filing
Candel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that’s heading to the FDA for marketing approval later this...
-
Uncategorized4 weeks agoOpinion: First hantavirus, now Ebola: What two outbreaks reveal about global preparedness
The reports emerging this week of a major Ebola outbreak in the Democratic Republic of Congo, coming alongside a growing hantavirus outbreak linked to a cruise...
-
Uncategorized4 weeks ago
Employment and funding growth fell in 2025: California Life Sciences report
California life sciences jobs declined 1.8% last year, according to the new California Life Sciences sector report. While National Institutes of Health funding and venture capital...
-
Uncategorized4 weeks ago
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset
Plus, news about Tenaya’s TN-401 and Taiho’s Inqovi. 📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placed a full clinical hold...
-
Uncategorized4 weeks ago
Sun Pharma recalls cancer drug after finding glass particles in some vials
A batch of a chemotherapy product made at a Sun facility with a history of quality and compliance issues is being withdrawn from the U.S. market.
STAT+: Up and down the ladder: The latest comings and goings
FDA imposes import alert on Indian plant after inspectors flag GMP failings
